↓ Skip to main content

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Overview of attention for article published in BMC Cancer, September 2020
Altmetric Badge

Mentioned by

reddit
1 Redditor

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
33 Mendeley